Want to see AU:CBL full AI Analyst Report?
Top Page
Control Bionics Ltd.
(Sydney:CBL)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.06
â–˛(5.00% Upside)
Action:Reiterated
Date:08/29/26
The score is weighed down primarily by weak financial performance—persistent large losses, negative free cash flow, and a negative gross margin in 2026—plus a deteriorating revenue trend. Technicals also remain bearish with the price below major moving averages and negative MACD. Valuation does not provide support because earnings are negative and there is no indicated dividend yield.
Positive Factors
Low Financial Leverage
Modest leverage gives Control Bionics greater financial flexibility than a heavily indebted business and limits the immediate burden of debt servicing. This conservative capital structure can help preserve strategic options while management works to improve profitability and cash generation.
Negative Factors
Revenue Deterioration
The recent revenue decline weakens operating scale and makes it harder for the company to absorb fixed costs, invest in product development, or build a path toward breakeven. Volatile and deteriorating sales also reduce confidence that growth is currently durable over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Modest leverage gives Control Bionics greater financial flexibility than a heavily indebted business and limits the immediate burden of debt servicing. This conservative capital structure can help preserve strategic options while management works to improve profitability and cash generation.
Read all positive factors
Control Bionics Ltd. (CBL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$35.30M
Dividend YieldN/A
Average Volume (3M)383.78K
Price to Earnings (P/E)―
Beta (1Y)-0.06
Revenue Growth-22.43%
EPS Growth15.02%
CountryAU
Employees25
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.02
Shares Outstanding543,088,700
10 Day Avg. Volume267,235
30 Day Avg. Volume383,776
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)4.35
Price to Sales (P/S)5.76
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Control Bionics Ltd. Business Overview & Revenue Model
Company Description
Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the Ne...
Control Bionics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.77M | 6.14M | 5.35M | 5.64M | 4.50M |
| Gross Profit | -4.14M | 4.11M | 3.90M | 3.71M | -2.91M |
| EBITDA | -7.29M | -4.97M | -5.01M | -5.14M | -6.01M |
| Net Income | -7.27M | -6.11M | -5.91M | -5.63M | -6.11M |
Balance Sheet | |||||
| Total Assets | 9.05M | 8.23M | 9.03M | 8.70M | 13.44M |
| Cash, Cash Equivalents and Short-Term Investments | 2.08M | 672.66K | 980.76K | 935.50K | 5.21M |
| Total Debt | 618.92K | 435.40K | 961.74K | 128.50K | 284.82K |
| Total Liabilities | 2.73M | 2.72M | 2.76M | 1.58M | 1.51M |
| Stockholders Equity | 6.31M | 5.51M | 6.27M | 7.15M | 11.92M |
Cash Flow | |||||
| Free Cash Flow | -5.76M | -4.57M | -5.38M | -4.98M | -5.75M |
| Operating Cash Flow | -5.75M | -4.27M | -4.91M | -4.53M | -5.60M |
| Investing Cash Flow | -269.80K | -744.78K | -473.09K | -457.54K | -147.74K |
| Financing Cash Flow | 7.49M | 4.63M | 5.43M | 706.43K | -87.33K |
Control Bionics Ltd. Technical Analysis
Positive
0.06
Price Trends
0.06
Positive
0.07
Positive
0.06
Positive
Market Momentum
<0.01
Negative
88.91
Negative
76.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Positive. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 88.91 is Negative, neither overbought nor oversold. The STOCH value of 76.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CBL.
Control Bionics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$8.47B | 56.67 | 8.01% | 2.67% | -0.90% | -62.14% | |
57 Neutral | AU$51.94M | 227.27 | 0.93% | ― | 18.54% | ― | |
52 Neutral | AU$38.46M | -8.68 | -28.79% | 185.34% | 19.13% | 58.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$145.01M | -18.18 | -46.84% | ― | ― | 20.40% | |
44 Neutral | AU$35.30M | -3.33 | -103.48% | ― | -22.43% | 15.02% | |
44 Neutral | AU$22.62M | -2.95 | -201.54% | ― | -100.00% | 50.49% |
* Healthcare Sector Average
AU:CBL
Control Bionics Ltd.
0.07
0.02
53.49%
AU:EYE
Nova Eye Medical
0.14
-0.03
-18.18%
AU:COH
Cochlear
129.00
-147.08
-53.27%
AU:CMP
Compumedics Limited
0.26
-0.05
-17.46%
AU:NTI
Neurotech International
0.01
>-0.01
-30.00%
AU:EMV
EMvision Medical Devices Ltd.
1.66
-0.20
-10.75%
Control Bionics Ltd. Corporate Events
Control Bionics Wins CE Mark for NeuroStrip, Expanding Access Across Europe
Oct 4, 2026
Control Bionics has secured CE marking for its NeuroStrip wearable sEMG device as a Class I medical device under the EU Medical Device Regulation, following its registration in the European Database on Medical Devices. This certification allows th...
Control Bionics flags ASX Listing Rule breach over Phoenix loan facility
Sep 28, 2026
Control Bionics has disclosed that it breached ASX Listing Rule 10.1 in relation to a $400,000 loan facility it accepted from substantial shareholder Phoenix Development Fund, which was to be secured over its anticipated FY26 RD tax incentive refu...
Control Bionics Sets October Date for 2026 AGM and Moves to Digital Meeting Materials
Sep 11, 2026
Control Bionics Limited has called its 2026 Annual General Meeting for 13 October in Sydney, inviting shareholders to attend or participate via proxy voting. The company is shifting to electronic distribution of meeting materials, with notices and...
Control Bionics Sets 2026 AGM to Vote on Board, Incentive Plans and Extra Capital Capacity
Sep 11, 2026
Control Bionics Limited has convened its 2026 Annual General Meeting for 13 October in Sydney, setting out standard governance items including consideration of its 2026 financial report and adoption of the remuneration report. Shareholders will al...
Control Bionics Issues 1.6 Million Unquoted XV Options
Sep 7, 2026
Control Bionics Limited has notified the market of the issue of 1,600,000 unquoted XV Options, effective 7 September 2026, under a new class of securities to be confirmed on the ASX. The issuance of these options suggests the company is using equi...
Control Bionics Director Stephen Rix Increases Shareholding
Sep 1, 2026
Control Bionics director Stephen Rix has increased his holding in the company through an on-market purchase of additional ordinary shares. The transaction, conducted on 1 September 2026, lifted his total direct and indirect shareholding to 8,959,9...
Control Bionics sets cautious tone as it shifts from repositioning to growth
Aug 27, 2026
Control Bionics Ltd., listed on the ASX under ticker CBL, is a developer of assistive communication and neuro-based interface technologies designed for people with severe physical disabilities. Its solutions are used across healthcare and disabili...
Control Bionics Files Updated ASX Corporate Governance Statement
Aug 27, 2026
Control Bionics Limited has lodged its latest corporate governance statement for the year ended 30 June 2026, confirming it complies with ASX Listing Rule requirements by hosting the statement on its website and filing the accompanying Appendix 4G...
Control Bionics Sets Growth Agenda Around Unified Assistive Tech Platform
Aug 27, 2026
Control Bionics Limited’s latest annual report outlines a unified platform strategy supporting three commercial pillars in the assistive technology space. The company continues to focus on products that enable communication and device contro...
Control Bionics Posts Wider Loss as It Takes Full Control of U.S. Neurotech Unit
Aug 27, 2026
Control Bionics Limited reported a 22.4% decline in revenues from ordinary activities to $4.77 million for the year ended 30 June 2026, alongside an 18.9% increase in loss after tax to $7.27 million, as the group continues to invest in its assisti...
Control Bionics to unveil FY26 results with investor webcast
Aug 27, 2026
Control Bionics Limited will release its financial results for the full year ended 30 June 2026 on Friday 28 August 2026, highlighting its performance as a neurotechnology specialist in non‑invasive neural‑signal platforms. The company...
Control Bionics Wins Key U.S. Medicare Code for UnoTouch Omni Speech Devices
Aug 26, 2026
Control Bionics has secured U.S. Medicare PDAC coding verification for two UnoTouch Omni speech generating devices, clearing the final regulatory hurdle for market access. The devices have been assigned HCPCS code E2510, the highest-value Medicare...
Control Bionics wins UK approval for NeuroStrip, advancing international expansion
Aug 25, 2026
Control Bionics Limited has secured registration from the UK Medicines and Healthcare products Regulatory Agency for its NeuroStrip wearable surface electromyography device, clearing the key regulatory barrier to commercial supply across Great Bri...
Control Bionics Issues New 2026 ESOP Options to Staff
Aug 12, 2026
Control Bionics Limited has notified the market of the issue of 2,333,331 unquoted employee share options under its 2026 Employee Share Option Plan. The new options, which will not be quoted on the ASX, are part of an incentive scheme designed to ...
Control Bionics Director Jeremy Steele Increases Shareholding via Placement
Aug 12, 2026
Control Bionics Limited has disclosed a change in director Jeremy Steele’s interests, with his combined direct and indirect holdings in ordinary shares increasing through the issue of placement shares. Steele, who is also a shareholder in J ...
Control Bionics Director Nicholas Opie Increases Indirect Shareholding via Placement
Aug 12, 2026
Control Bionics Limited has disclosed a change in director Nicholas Opie’s interests following shareholder approval of a recent capital raising. Through NL RS Opie Pty Ltd, an entity in which he is a director and shareholder, Opie has acqui...
Control Bionics Director Boosts Indirect Shareholding via Share Placement
Aug 12, 2026
Control Bionics director Damian Lismore has increased his indirect shareholding through Glenariff Superannuation P/L, acquiring 320,000 ordinary shares via a placement for $24,000. Following the transaction on 12 August 2026, his indirect holdings...
Control Bionics Director Increases Stake Through Share Placement
Aug 12, 2026
Control Bionics has disclosed a change in director Stephen Rix’s interests, with his combined direct and indirect holding in ordinary shares increasing through the issue of placement shares. Rix acquired 2,040,000 new shares for $153,000, li...
Control Bionics Expands Capital Base With Major Share Issuance
Aug 12, 2026
Control Bionics Limited has issued 97,771,039 fully paid ordinary shares, significantly expanding its share base as part of a capital management initiative. The shares were issued without a prospectus or product disclosure statement, relying inste...
Control Bionics Seeks ASX Quotation for Nearly 98 Million New Shares
Aug 11, 2026
Control Bionics Ltd. has applied to the ASX for quotation of 97,771,039 new ordinary fully paid shares under the code CBL, with an issue date of 12 August 2026. The large volume of shares being quoted is expected to expand the company’s trad...
Control Bionics launches NeuroStrip app to drive global scale
Aug 11, 2026
Control Bionics has expanded access to its proprietary NeuroStrip wearable surface electromyography platform by launching a free app on Apple’s App Store, the Mac App Store and the Microsoft Store. The move allows clinicians, physiotherapist...
Control Bionics Grants 1.25 Million Options to Non‑Executive Director
Aug 11, 2026
Control Bionics Ltd. has notified the market of the issue of 1,250,000 unquoted options to a non‑executive director, effective August 11, 2026. The grant of director options underscores the company’s use of equity‑based incentive...
Control Bionics Wins Strong Shareholder Backing for Major Capital Raisings
Aug 6, 2026
Control Bionics Limited reported the outcomes of a 6 August 2026 security holder meeting, where investors overwhelmingly backed multiple prior and future share issuances. Resolutions ratifying earlier placements in late 2025 and mid-2026, as well ...
Control Bionics’ NeuroStrip Wins FDA Medical Device Registration
Aug 3, 2026
Control Bionics has secured U.S. FDA registration and device listing for its NeuroStrip surface EMG wearable platform, formally positioning it as a medical device in one of the world’s largest healthcare markets. The move reinforces NeuroStr...
Control Bionics accelerates global rollout of assistive and neurotechnology platform
Jul 30, 2026
Control Bionics is building commercial momentum across its assistive technology and NeuroTechnology platform, underpinned by products such as NextLevel tablets, NeuroNode and NeuroStrip. The company is leveraging a wholesale and distributor-led st...
Control Bionics Raises $9.75m Through Placement and Share Purchase Plan
Jul 21, 2026
Control Bionics Limited has completed its Share Purchase Plan, receiving applications totalling $256,500 at an issue price of $0.075 per new share. The company will issue 3,419,993 new shares, which are expected to begin trading on the ASX the day...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.